Drug Trial Radar · NCT03440450
A Phase 1 Dose-escalation Study of FF-10832 for Treatment of Solid Tumors Including Biliary Tract Cancer
Last checked: Nov 19, 2026Latest source record: Sep 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
90
Actual
Start
Mar 22, 2018
Primary completion
Oct 2026
Study completion Mar 2027
Sponsor
- Lead sponsor
- Fujifilm Pharmaceuticals U.S.A., Inc.Industry
- Sponsor type
- Industry
- First posted
- Feb 22, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To determine the safety profile, maximum tolerated dose (MTD), dose-limiting toxicities (DLT) and recommended Phase 2 dose (RP2D) in patients who receive FF-10832 (Gemcitabine Liposome Injection) for treatment of advanced solid tumors including biliary tract cancer
Conditions
- Advanced Solid Tumors
- Biliary Tract Cancer
Interventions
FF-10832 Gemcitabine Liposome InjectionDrug
FF-10832 to be diluted in dextrose 5% in water (D5W) and intravenously infused at a continuous rate over 30 to 120 minutes
Primary outcomes
What the sponsor says the trial is designed to measure.
- Determine incidence of Treatment Emergent Adverse Events (TEAE)Time frame: 2.5 years
- Identify dose-limiting toxicities (DLT) of FF-10832Time frame: 2.5 years
- Determine maximun tolerated dose (MTD) of FF-10832Time frame: 2.5 years
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
Honor Health Research Institute
Scottsdale, Arizona
University of Arizona Cancer Center
Tucson, Arizona
Hoag Memorial Hospital Comprehensive Cancer Center
Newport Beach, California
Sarah Cannon Research Institute
Denver, Colorado
Sarah Cannon Research Institute
Nashville, Tennessee
MD Anderson Cancer Research Center
Houston, Texas
Virginia Mason Medical Center
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.